NCT02347176

Phase 2 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults With Atopic Dermatitis

A Phase 2b, Randomized, Double-blinded, Placebo-controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of Tralokinumab in Adult Subjects With Moderate-to-Severe Atopic Dermatitis

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 204 (actual)
• Sponsor: MedImmune LLC · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The aim of the study is to evaluate the efficacy and safety of tralokinumab in adults with atopic dermatitis

Conditions

• Atopic Dermatitis

Interventions

Type	Name	Description
OTHER	Placebo	Subcutaneous injection with placebo
BIOLOGICAL	Tralokinumab Dose 1	Subcutaneous injection with tralokinumab
BIOLOGICAL	Tralokinumab Dose 2	Subcutaneous injection with tralokinumab
BIOLOGICAL	Tralokinumab Dose 3	Subcutaneous injection with tralokinumab

Timeline

• Start date: 2015-01-23
• Primary completion: 2015-11-27
• Completion: 2016-02-05
• First posted: 2015-01-27
• Last updated: 2018-05-23
• Results posted: 2017-06-07

Locations

57 sites across 6 countries: United States, Australia, Canada, Germany, Japan, Poland